Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MMP12 | P39900 | 2/20 | 0.50 |
| ▸ | MMP13 | P45452 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | AHR | P35869 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | BCAT1 | P54687 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29886865 | 1.00 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1HPGDMEN1MAPT | |
| SCHEMBL6525933 | 0.91 | L3MBTL1 (0.51) | SMN1; SMN2ALDH1A1HPGDMEN1MAPT | |
| SCHEMBL3072615 | 0.89 | TSHR (0.56) | SMN1; SMN2ALDH1A1HPGDMEN1MAPT | |
| SCHEMBL3118164 | 0.85 | TSHR (0.47) | SMN1; SMN2ALDH1A1HPGDMEN1MAPT | |
| SCHEMBL27576468 | 0.82 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1HPGDMEN1MAPT | |
| SCHEMBL2818655 | 0.82 | SMN1; SMN2 (0.63) | SMN1; SMN2ALDH1A1HPGDMEN1MAPT | |
| SCHEMBL4238589 | 0.82 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1HPGDMEN1MAPT | |
| SCHEMBL9338410 | 0.81 | NPC1 (0.50) | SMN1; SMN2ALDH1A1HPGDMEN1MAPT | |
| SCHEMBL23673449 | 0.81 | AHR (0.54) | SMN1; SMN2AHRBCAT1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL9145969 | 0.81 | SMN1; SMN2 (0.61) | SMN1; SMN2ALDH1A1HPGDMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11304924-B2 | Pharmaceutical compositions comprising nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| WO-2021147882-A1 | DIBENZOFURAN DERIVATIVE CATHEPSIN K INHIBITOR, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2021-07-29 | — | — | WO | disclosed |
| WO-2021147882-A1 | DIBENZOFURAN DERIVATIVE CATHEPSIN K INHIBITOR, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2021-07-29 | — | — | WO | disclosed |
| US-10548872-B2 | Pharmaceutical compositions comprising nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190224159-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. | 2019-07-25 | — | — | US | disclosed |
| US-10245249-B2 | Pharmaceutical compositions comprising nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2019-04-02 | — | — | US | disclosed |
| EP-2945621-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20150366977-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. | 2015-12-24 | — | — | US | disclosed |
| EP-0853618-B1 | SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N- (AMINOIMINOMETHYL)PHENYLALKYL -AZAHETEROCYCLYLAMIDE COMPOUNDS | AVENTIS PHARMA INC (US) | 2011-08-17 | — | — | EP | disclosed |
| CN-101052919-B | Sulfonate-containing composition for forming anti-reflective coating for lithography | NISSAN CHEMICAL IND LTD | 2011-05-25 | — | — | CN | disclosed |
| US-5594021-A | VASOCONSTRICTORS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
| WO-1996040679-A1 | SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040672-A1 | COMBINATORIAL LIBRARIES HAVING AMINODIOL MONOMER SUBUNITS | ISIS PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5571821-A | CARDIOVASCULAR DISORDERS TO MODULATE ENDOTHELIN, HYPOTENSIVE AGENTS AND VASOCONSTRICTION | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-11-05 | — | — | US | disclosed |
| WO-1996031492-A1 | THIENYL-, FURYL-, PYRROLYL- AND BIPHENYLSULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-10-10 | — | — | WO | disclosed |
| US-5391556-A | Thrombin inhibitors | KARL THOMAE GMBH (DE) | 1995-02-21 | — | — | US | disclosed |
| EP-0555824-A1 | N-alpha-arylsulfonylated benzimidazolylalaninamide derivatives, medicaments based thereon and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1993-08-18 | — | — | EP | disclosed |
| EP-0178183-B1 | PREPARATION OF AROMATIC KETONE-SULFONE COPOLYMERS | RAYCHEM CORPORATION (a Delaware corporation) (US) | 1993-01-20 | — | — | EP | disclosed |
| US-4593086-A | From carboxylic acid halide and aromatic dicarboxylic acid dihalide | RAYCHEM CORPORATION (US) | 1986-06-03 | — | — | US | disclosed |
| EP-0178183-A2 | Preparation of aromatic ketone-sulfone copolymers | RAYCHEM CORPORATION (a Delaware corporation) (US) | 1986-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10548872-B2 | Pharmaceutical compositions comprising nitroxyl donors | TNNT2, TNNI3, NQO1 | SMN1; SMN2 793/4885ALDH1A1 954/4885HPGD 24/4885 |
| US-10245249-B2 | Pharmaceutical compositions comprising nitroxyl donors | TNNT2, TNNI3, NQO1 | SMN1; SMN2 793/4885ALDH1A1 954/4885HPGD 24/4885 |
| US-20150366977-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | TNNT2, TNNI3, NQO1 | SMN1; SMN2 793/4885ALDH1A1 954/4885HPGD 24/4885 |
| US-11304924-B2 | Pharmaceutical compositions comprising nitroxyl donors | TNNT2, TNNI3, NQO1 | SMN1; SMN2 793/4885ALDH1A1 954/4885HPGD 24/4885 |
| US-20190224159-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NITROXYL DONORS | TNNT2, TNNI3, NQO1 | SMN1; SMN2 793/4885ALDH1A1 954/4885HPGD 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.